MAGE-A3 expression is an adverse prognostic factor in diffuse large B-cell lymphoma

被引：12

作者：

Olarte, Irma ^{[1
]}

Martinez, Adolfo ^{[1
]}

Ramos-Penafiel, Christian ^{[1
]}

Castellanos-Sinco, Humberto ^{[1
]}

Zamora, Jorge ^{[1
]}

Collazo-Jaloma, Juan ^{[1
]}

Gutierrez, Mario ^{[1
]}

Gutierrez-Kobeh, Laila ^{[2
]}

Chavez-Olmos, Pedro ^{[3
]}

Manzanilla, Hugo ^{[4
]}

Garrido-Guerrero, Efrain ^{[3
]}

Ordonez-Razo, Rosa M. ^{[5
]}

Miranda, Enrique I. ^{[1
,6
]}

机构：

[1] Hosp Gen Mexico City, Serv Hematol, Lab Biol Mol, Mexico City 06726, DF, Mexico

[2] Univ Nacl Autonoma Mexico, Sch Med, Mexico City, DF, Mexico

[3] CINVESTAV IPN, Dept Genet & Biol Mol, Mexico City, DF, Mexico

[4] Hosp Gen Mexico City, Serv Urol, Mexico City 06726, DF, Mexico

[5] IMSS, Ctr Med Siglo 21, Hosp Pediat, Unidad Invest Med Genet Humana, Mexico City, DF, Mexico

[6] Westhill Univ, Sch Med, Mexico City, DF, Mexico

来源：

HEMATOLOGY | 2011年 / 16卷 / 06期

关键词：

MAGE-A3; Expression; Prognostic; DLBCL; Lymphoma; NON-HODGKINS-LYMPHOMA; TISSUE MICROARRAY; GENE-EXPRESSION; CANCER; CHEMOTHERAPY; PREDICTION; CARCINOMA; SURVIVAL; MYELOMA; ANTIGEN;

D O I：

10.1179/102453311X13085644680384

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

This study evaluates the prognostic value of MAGE-A3 expression in 28 diffuse large B-cell lymphoma (DLBCL) patients. A significant association was observed between MAGE-A3 expressions, assessed by quantitative real-time RT-polymerase chain reaction (PCR), with advanced stages of disease (P<0.05). Elevated serum lactate dehydrogenase (LDH) levels and International Prognostic Index (IPI) score were significantly higher in MAGE-A3-positive patients (P=0.025 and P=0.004, respectively). Expression of MAGE-A3 was associated with poor response to treatment and a significantly shorter overall survival (P<0.001). Our data address new information in the association of MAGE-A3 expression and poor prognosis in DLBCL patients.

引用

页码：368 / 372

页数：5

共 50 条

[1] CD43 Expression Is an Adverse Prognostic Factor in Diffuse Large B-Cell Lymphoma
Mitrovic, Zdravko
Ilic, Ivana
Nola, Marin
Aurer, Igor
Sonicki, Zdenko
Basic-Kinda, Sandra
Radman, Ivo
Ajdukovic, Radmila
Labar, Boris
CLINICAL LYMPHOMA & MYELOMA, 2009, 9 (02): : 133 - 137
[2] Loss of RUNX3 expression is an independent adverse prognostic factor in diffuse large B-cell lymphoma
Duncan, Virginia E.
Ping, Zheng
Varambally, Sooryanarayana
Peker, Deniz
LEUKEMIA & LYMPHOMA, 2017, 58 (01) : 179 - 184
[3] Lymphopenia Is an Adverse Prognostic Factor in EBV-Positive Diffuse Large B-Cell Lymphoma
Beltran, Brady E.
Chavez, Julio C.
Sotomayor, Eduardo M.
Castillo, Jorge J.
BLOOD, 2014, 124 (21)
[4] Expression of BMI-1 is a poor prognostic factor in diffuse large B-cell lymphoma
Hukku, S.
Almiski, S.
Vakil, H.
Kurre, A.
Levi, E.
LABORATORY INVESTIGATION, 2008, 88 : 257A - 258A
[5] Expression of BMI-1 is a poor prognostic factor in diffuse large B-Cell lymphoma
Hukku, S.
Almiski, S.
Vakil, H.
Kurrer, A.
Levi, E.
MODERN PATHOLOGY, 2008, 21 : 257A - 258A
[6] Expression of Myc, but not pSTAT3, is an adverse prognostic factor for diffuse large B-cell lymphoma treated with epratuzumab/R-CHOP
Gupta, Mamta
Maurer, Matthew J.
Wellik, Linda E.
Law, Mark E.
Han, Jing Jing
Ozsan, Nazan
Micallef, Ivana N.
Dogan, Ahmet
Witzig, Thomas E.
BLOOD, 2012, 120 (22) : 4400 - 4406
[7] Cyclin D3 is a predictive and prognostic factor in diffuse large B-cell lymphoma
Filipits, M
Jaeger, U
Pohl, G
Stranzl, T
Simonitsch, I
Kaider, A
Skrabs, C
Pirker, R
CLINICAL CANCER RESEARCH, 2002, 8 (03) : 729 - 733
[8] Prognostic factors in diffuse large B-cell lymphoma
Niitsu, Nozomi
INTERNAL MEDICINE, 2006, 45 (05) : 227 - 228
[9] Prognostic models for diffuse large B-cell lymphoma
Conconi, A
Zucca, E
Roggero, E
Bertoni, F
Bernasconi, A
Mingrone, W
Pedrinis, E
Cavalli, F
HEMATOLOGICAL ONCOLOGY, 2000, 18 (02) : 61 - 73
[10] Tumor Mutational Burden As a Prognostic Factor in Diffuse Large B-Cell Lymphoma
Griffin, Rosalie
Wenzl, Kerstin
Sarangi, Vivekananda
Rimsza, Lisa M.
King, Rebecca
Feldman, Andrew L.
Maurer, Matthew J.
Nowakowski, Grzegorz S.
Link, Brian K.
Habermann, Thomas M.
Stong, Nicholas
Huang, C. Chris
Gandhi, Anita K.
Slager, Susan L.
Novak, Anne J.
Cerhan, James R.
BLOOD, 2023, 142

← 1 2 3 4 5 →